LDL-C vs hsCRP vs HDL-C: What is the Primary Driver of Benefit?

When considering biomarkers such as LDL-C, hsCRP and HDL-C, it is of interest to know their usefulness for predicting the risk of future vascular events, and for monitoring drug effectiveness. There is data to suggest that hsCRP may be a better predictor of the...(more)

Inflammation and Novel Risk Markers – From Acute Coronary Syndromes to Primary Prevention

There are different diagnostic strategies for the evaluation of acute chest pain, each of which is based on a different pathophysiology. Dr. Ridker, however, suggests that there are better ways to deal with risk stratification in acute ischemia. The multimarker...(more)

How to Predict Your Risk of Heart Attack or Stroke: The Reynolds Risk Score - Bringing hsCRP and Genetics to Clinical Practice

What is the actual prevalence of major risk factors in patients with coronary heart disease? A study by Khot et al. published in the JAMA in 2003 revealed that about 60 percent of these patients have only one or none of the conventional risk factors such as...(more)

A Comparison of hsCRP and Lp-PLA2 as Biomarkers to Assist in the Detection and Treatment of Cardiovascular Disease

The use of suitable biomarkers to enhance risk stratification of those at intermediate risk from global risk assessment for cardiovascular disease has an important role, since a large proportion of all cardiovascular events occur among those at intermediate risk....(more)

Should I Use Biomarkers in Assessing Cardiovascular Risk? Where did we start, where are we now, and where are we going?

In this presentation Dr. Ridker talks about biomarkers and cardiovascular risk, and where high-sensitivity C-reactive protein (hsCRP) may play a role clinically. Several biomarkers have been independently associated with the future risk of myocardial infarction...(more)

Prediction and Prevention: Where might hsCRP Fit In?

The prevalence of conventional risk factors in patients with coronary heart disease is not uniform. Dr. Ridker discusses the Framingham risk score, which is used to predict the risk of cardiovascular events in patients and to determine whether therapy should be...(more)

Use of Surrogate Outcomes, Surrogate Endpoints, and Biomarkers in Randomized Clinical Trials of Cardiovascular Disease: Does hsCRP Have A Role

In this presentation, Dr. Ridker explores three questions: Can we rely on surrogate outcomes in clinical trials? Can we rely on surrogate endpoints in clinical trials?..And if not, is there any use for biomarkers such as C-reactive protein (CRP) in the phase III...(more)

Blood Pressure, Blood Pressure Therapy, and C-Reactive Protein (hsCRP): A Patient Based Update

Inflammation is a process by which the body heals itself, however, chronic inflammation is implicated in some disease states, such as rheumatoid arthritis. Recently, atherosclerosis has also come to be understood as an inflammatory disease (1). C-reactive...(more)

Valsartan, Blood Pressure Reduction, and C-Reactive Protein: Primary Report of the Val-MARC Trial

In this presentation Dr. Ridker discusses new findings from the Val-MARC (Valsartan – Managing BP Agressively and Evaluating Reductions in hsCRP) trial that were presented at the 21st Annual Scientific Meeting of the American Society of Hypertension, in New York....(more)

Non-HDL Cholesterol, Apolipoproteins A-1 and B-100, Standard Lipid Measures, Lipid Ratios, and CRP as Risk Factors for Cardiovascular Disease in Women

In this presentation Dr. Ridker discusses new data from a large prospective study directly comparing the predictive value of different lipid measures, lipid ratios, Apolipoproteins A-1 and B-100, non-HDL cholesterol and hsCRP, for future cardiovascular events in...(more)

Should We Measure hsCRP After Starting Statin Therapy? Update 2005

With regards to assessment of cardiovascular risk, hsCRP levels add prognostic information to that obtained from the Framingham risk score (1). Statin drugs are cholesterol-lowering agents that also lower CRP levels (2), and the Cholesterol and Recurrent Events...(more)

Do patients on statin therapy need hsCRP measured? Update January 2005

High sensitivity C-reactive protein (hsCRP) is a measuement of inflammation, and numerous large studies have shown that high hsCRP levels increase the risk of having a future heart attack or stroke. As a result of these data, doctors can now use hsCRP measurements...(more)

C-Reactive Protein (hsCRP), Inflammation, and Cardiovascular Risk: Why the VAL-MARC Trial?

As early as 1997 it was reported that baseline high-sensitivity C-reactive protein (hs-CRP) levels predicted the risk of heart attack and stroke in apparently healthy men (1). These findings were confirmed in a large study of healthy women, which additionally...(more)

An Introduction to High-Sensitivity C-Reactive Protein (hs-CRP) for Patients: Can We Better Predict Heart Attack and Stroke?

In this presentation Dr. Ridker addresses the question of whether high-sensitivity C-reactive protein (hs-CRP) can be used to better predict the risk of heart attack and stroke. High blood pressure, smoking, diabetes and high cholesterol are classical risk...(more)

CRP, Inflammation, and its Relationship to Cardiovascular Disease, Metabolic Syndrome and Type 2 Diabetes

In this presentation Dr Ridker reviews the use of high-sensitivity C-Reactive Protein (hs-CRP) as a prognostic indicator of myocardial infarction, stroke and type 2 diabetes; the added prognostic information CRP provides in patients with the metabolic syndrome, the...(more)

CRP, Statins, and Coronary Risk: Why the JUPITER Trial?

In this presentation Dr Ridker gives an update on the role of high sensitivity C-Reactive Protein (hs-CRP) in predicting the risk of heart attack and stroke, and the role of statin therapy in modulating that risk. CRP, a marker of inflammation, has become a...(more)